Published in Blood on January 05, 2006
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr (2010) 1.62
Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem (2011) 1.57
Appraisal of immunoglobulin free light chain as a marker of response. Blood (2008) 1.38
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol (2011) 1.24
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol (2011) 1.14
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc (2012) 1.09
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood (2010) 1.08
Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol (2013) 1.06
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation (2010) 1.04
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia (2010) 1.03
Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One (2009) 1.01
Light chain amyloidosis - current findings and future prospects. Curr Protein Pept Sci (2009) 0.96
Current treatment of AL amyloidosis. Haematologica (2009) 0.95
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol (2011) 0.93
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia (2015) 0.88
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev (2009) 0.85
Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood (2007) 0.83
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica (2015) 0.81
Amyloidosis and POEMS syndrome. Expert Opin Pharmacother (2010) 0.81
Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). J Am Soc Echocardiogr (2011) 0.78
Diagnostic dilemma in a case of osteolytic lesions. BMJ Case Rep (2014) 0.78
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood (2014) 0.77
Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant (2008) 0.77
Response of hemorrhagic bullous skin lesions of the breast secondary to primary systemic amyloidosis to a five-drug combination chemotherapy: a case report and review of the literature. Exp Hematol Oncol (2012) 0.77
Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant (2015) 0.77
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. Am J Hematol (2014) 0.76
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica (2015) 0.75
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart (2017) 0.75
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol (1995) 5.51
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med (2004) 4.05
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem (2001) 3.94
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res (2004) 2.25
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet (2003) 1.64
Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol (2003) 1.55
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant (2005) 1.55
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood (1998) 1.48
Response rates and survival in primary systemic amyloidosis. Blood (1991) 1.27
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant (2004) 1.26
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Multiple myeloma. Blood (2008) 5.88
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Narrative review: the systemic capillary leak syndrome. Ann Intern Med (2010) 3.71
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood (2007) 3.52
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol (2009) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood (2006) 3.04